- Home
- LTRN vs SLGL Comparison
LTRN vs SLGL Comparison
Compare LTRN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- SLGL
- Stock Information
- Founded
- LTRN 2013
- SLGL 1997
- Country
- LTRN United States
- SLGL Israel
- Employees
- LTRN N/A
- SLGL N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- SLGL Health Care
- Exchange
- LTRN Nasdaq
- SLGL Nasdaq
- Market Cap
- LTRN 36.0M
- SLGL 19.3M
- IPO Year
- LTRN 2020
- SLGL 2018
- Fundamental
- Price
- LTRN $3.16
- SLGL $7.26
- Analyst Decision
- LTRN Strong Buy
- SLGL Buy
- Analyst Count
- LTRN 1
- SLGL 1
- Target Price
- LTRN $25.00
- SLGL $40.00
- AVG Volume (30 Days)
- LTRN 50.9K
- SLGL 25.5K
- Earning Date
- LTRN 08-07-2025
- SLGL 08-15-2025
- Dividend Yield
- LTRN N/A
- SLGL N/A
- EPS Growth
- LTRN N/A
- SLGL N/A
- EPS
- LTRN N/A
- SLGL N/A
- Revenue
- LTRN N/A
- SLGL $12,103,000.00
- Revenue This Year
- LTRN N/A
- SLGL N/A
- Revenue Next Year
- LTRN N/A
- SLGL $31.17
- P/E Ratio
- LTRN N/A
- SLGL N/A
- Revenue Growth
- LTRN N/A
- SLGL 603.66
- 52 Week Low
- LTRN $2.55
- SLGL $3.34
- 52 Week High
- LTRN $6.12
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- LTRN 46.11
- SLGL 52.97
- Support Level
- LTRN $3.05
- SLGL $7.02
- Resistance Level
- LTRN $3.33
- SLGL $7.58
- Average True Range (ATR)
- LTRN 0.18
- SLGL 0.37
- MACD
- LTRN 0.01
- SLGL 0.02
- Stochastic Oscillator
- LTRN 26.19
- SLGL 41.28
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.